Physician profile
James Callaghan
NPI 1528275443
$3,128.13
in general payments reported to CMS, 2019-2025
27 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $204 · 2021: $86.27 · 2023: $561 · 2024: $819 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $403.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $374.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $365.61 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $317.78 | 2020-2025 | |
| Glaxosmithkline, LLC. | $220.49 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.92 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Pfizer INC. | $160.24 | 2019-2025 | |
| Exact Sciences Corporation | $155.84 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $128.14 | 2023 | Intellis Adaptivestim |
| Averitas Pharma INC. | $113.77 | 2023 | Qutenza |
| Amgen INC. | $88.51 | 2019-2025 | Evenity, Prolia, Otezla |
| Astellas Pharma US INC | $74.75 | 2023-2024 | Veozah |
| Dexcom, INC. | $71.56 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $57.83 | 2019-2025 | Gardasil 9, Proquad, Capvaxive |
| Smith+Nephew, INC. | $53.59 | 2020-2024 | Collagenase Santyl, Regranex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $48.74 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $42.53 | 2019-2020 | |
| Organogenesis INC. | $37.81 | 2019-2025 | Puraply Wound Matrix |
| Amarin Pharma, INC. | $34.96 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $33.21 | 2025 | Gemtesa |
| Integra Lifesciences Corporation | $32.59 | 2019 | |
| Reddress USA, INC. | $32.05 | 2021 | |
| Alnylam Pharmaceuticals INC. | $27.80 | 2025 | Onpattro |
| Solventum Corporation | $24.28 | 2024 | Activ.A.C. |
| Kci USA, INC. | $18.79 | 2020 | |
| Allergan, INC. | $17.95 | 2019 | |
| Shire North American Group INC | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Callaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.